Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study

Main Article Content

K Reich
Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation? Center, Hamburg, Germany

K Papp
Probity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada

A Blauvelt
Oregon Medical Research Center, Portland, OR

R Langley
Dalhousie University, Halifax, NS, Canada

A Armstrong
Keck School of Medicine of USC, Dermatology, Los Angeles, CA

RB Warren
The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, UK

K Gordon
Medical College of Wisconsin, Milwaukee, WI

JF Merola
Department of Dermatology, Brigham and Women?s Hospital and Harvard Medical School, Boston, MA

C Madden
UCB Pharma, Raleigh, NC

M Wang
UCB Pharma, Raleigh, NC

V Vanvoorden
UCB Pharma, Brussels, Belgium

M Lebwohl
Icahn School of Medicine, New York, NY

Keywords

Psoriasis, Plaque Psoriasis, Biologic, Il-17A, Il-17F, Bimekizumab

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Johnston A. et al. J Immunol 2013;190:2252–62

4. Papp K. et al. JAAD 2018;79:277–86, NCT02905006

5. Blauvelt A. et al. AAD 2019 (OP11180), NCT03010527

6. FDA Briefing Document, Dermatologic and Opthalmic Drugs Advisory Committee, July 19 2016

7. Kerkhof PC. et al. JAAD 2016; 75:83–98

8. Australian Public Report for Ixekizumab, May 2017

9. Glatt S. et al. Br J Clin Pharm 2017;83(5):991–1001

10. Glatt S. et al. Ann Rheum Dis 2018;77:523–32.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.82

Article Details

How to Cite
Reich, K., Papp, K., Blauvelt, A., Langley, R., Armstrong, A., Warren, R., Gordon, K., Merola, J., Madden, C., Wang, M., Vanvoorden, V., & Lebwohl, M. (2020). Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. SKIN The Journal of Cutaneous Medicine, 4(6), s82. https://doi.org/10.25251/skin.4.supp.82
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 > >>